The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing you cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

BRESHAP as second-line therapy for R/R HL patients

Feb 6, 2019
Share:

On 10 January 2019, Ramon Garcia-Sanz from University Hospital Salamanca, Salamanca, SP and colleagues, published in Annals of Oncology the long-term results of a phase I-II trial performed by the Spanish GELTAMO group (NCT02243436).

In this phase I-II trial the efficacy and safety of brentuximab vedotin (BV) in combination with etoposide, solumedrol, high-dose AraC, and cisplatin (ESHAP; BRESHAP) were investigated as second line treatment for relapsed or refractory (R/R) Hodgkin lymphoma (HL) patients. The initial analysis of this trial was published in Blood (2016). The primary endpoints of this long-term follow-up analysis were overall and complete response prior autologous stem cell transplantation (ASCT), as well as maximum tolerable dose (MTD). Secondary endpoints included overall survival (OS), progression-free survival (PFS), and time-to-tumor progression (TTP).

Study design & baseline characteristics 

  • N = 66 R/R HL patients after first-line chemotherapy
  • Dosing:
    • ESHAP (three 21-day cycles):
      • Etoposide: 40 mg/m2 (2h intravenous infusion) on Days 1−4
      • Cisplatin: 25 mg/m2 (24h infusion) on Days 1−4
      • Methylprednisolone: 250 mg per day (15 min intravenous infusion) on Days 1−4
      • Cytarabine: 2 g/m2 (2h intravenous infusion) on Day 5
    • BV: was administered on Day 1 in one of three dose levels (DL1, 0.9 mg/kg; DL2, 1.2 mg/kg; DL3, 1.8 mg/kg) on Day -1. Final BV dose was 1.8 mg/kg
    • Patients responding to BRESHAP proceeded to ASCT, followed by three BV courses. The first dose was administered on Day 28 post-transplant (1.8 mg/kg) and the rest every 21 days
  • Dose-limiting toxicity (DLT) was defined before transplant as any non-hematological toxicity episode of Grade ≥ 3, or any hematological toxicity episode of Grade ≥ 4 lasting for > 21 days
  • Median patients age (range): 36 (18−66) years
  • Sex: n = 35 females, n = 31 males
  • At infusion:
    • Primary refractory patients: n = 40
    • Patients with early relapses (complete response [CR] lasting less than one year): n = 16
    • Patients with late relapses (CR lasting ≥ 1): n = 10

Key findings 

Phase II data (n = 66):

  • The first three treatment cycles were administered to all patients with a median time from first to second cycle, and from second to third cycle of 21 days, respectively
  • Objective response (OR) rate prior transplant (n = 60): 91% (95% CI, 84−98%)
    • CR: 70% (95% CI, 59−81%)
    • Partial response (PR): 21% (95% CI, 11−31)
    • Stable disease (SD): n = 2
    • Disease progression (PD): n = 3
    • Death prior to evaluation: n = 1
  • CR was less frequently achieved in patients with PD under first-line treatment, who had bone marrow involvement or who were at disease stage IV at inclusion
  • Four months post ASCT, responses were seen:
    • CR: n = 49 patients
    • PR: n = 6 patients
    • PD: n = 10 patients
    • Death prior to evaluation: n = 1
  • At a median follow-up of 27 months:
    • Patients with PD: n = 16
    • Death without PD: n = 3
    • PFS: 71% (95% CI, 65−77%)
  • 30-month TTF: 74% (95% CI, 68−80%)
  • Projected 30-month OS: 91% (95% CI, 84−98%)
  • No differences in TTF or PFS were observed between DL2 and DL3 groups
  • TTF was significantly influenced by:
    • Response to BRESHAP
    • Haemoglobin < 12.5 g/dL
    • Extranodal disease at inclusion
    • Bone marrow involvement at inclusion
  • Stem cell mobilization was performed in n = 64 patients after the first (n = 15), second (n = 36), or third (n = 13) treatment cycle
  • Six patients could not receive ASCT due to early death
  • ASCT after BRESHAP was carried out in n = 60 patients (all engrafted)

Safety

  • During this follow-up, 39 serious adverse events (SAEs) occurred in n = 22 patients
  • The most common SAEs were:
    • Fever: n = 25 (35% neutropenic)
    • Hypomagnesemia and gastrointestinal symptoms: n = 3
  • Three SAEs led to death (pneumonia, n = 1; abdominal sepsis, n= 1; pulmonary embolism, n = 1)
  • All deaths were deemed as unrelated to BV protocol inclusion
  • Grade 3−4 hematological AEs occurred in 28 cases (apart from ASCT):
    • Neutropenia: n = 21
    • Thrombocytopenia: n = 14
    • Anemia: n = 7
  • Grade 3−4 non-hematological AEs occurred in 16 cases:
    • Non-neutropenic fever: n =13
    • Hypomagnesemia: n = 3
  • Peripheral neuropathy (PNP) was never present prior to ASCT, except in one patients who developed Grade 2 PNP after BRESHAP (fourth dose was not administered). Two more patients developed PNP after ASCT
  • In total, three patients discontinued BV due to PNP 

Conclusions

  • BRESHAP has a tolerable profile in R/R HL patients
  • BRESHAP could present an effective pre-transplant induction regimen for R/R HL patients, as it does not seem to affect transplantation success and leads to long-term remissions and OS
  1. Garcia-Sanz R. et al. Brentuximab Vedotin and ESHAP is Highly Effective as Second-Line Therapy for Hodgkin Lymphoma Patients (Long-Term Results of a Trial by the Spanish GELTAMO Group). Ann Oncol. 2019 Jan 18. DOI: 10.1093/annonc/mdz009 [Epub ahead of print].
Share: